SITAFLOXACIN MONOHYDRATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C19H18ClF2N3O3.H2O
Molecular Weight	427.83
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.N[C@@H]1CN(CC12CC2)C3=C(Cl)C4=C(C=C3F)C(=O)C(=CN4[C@@H]5C[C@@H]5F)C(O)=O

InChI

InChIKey=ANCJYRJLOUSQBW-JJZGMWGRSA-N

InChI=1S/C19H18ClF2N3O3.H2O/c20-14-15-8(17(26)9(18(27)28)5-25(15)12-4-10(12)21)3-11(22)16(14)24-6-13(23)19(7-24)1-2-19;/h3,5,10,12-13H,1-2,4,6-7,23H2,(H,27,28);1H2/t10-,12+,13+;/m0./s1

HIDE SMILES / InChI

Molecular Formula	C19H18ClF2N3O3
Molecular Weight	409.814
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21504249
Curator's Comment: description was created based on several sources, including http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1597 https://www.ncbi.nlm.nih.gov/pubmed/18806900 https://www.ncbi.nlm.nih.gov/pubmed/10588315

Sitafloxacin hydrate (DU-6859a, Gracevit), a new-generation, broad-spectrum oral fluoroquinolone that is very active against many Gram-positive, Gram-negative and anaerobic clinical isolates, including strains resistant to other fluoroquinolones, was recently approved in Japan for the treatment of respiratory and urinary tract infections. This is a new quinolone oral antibacterial to inhibit DNA replication of bacteria at the time of infection, and shows antibacterial action. Sitafloxacin is active against methicillin-resistant staphylococci, Streptococcus pneumoniae and other streptococci with reduced susceptibility to levofloxacin and other quinolones and enterococci. Sitafloxacin has also demonstrated activity against clinical isolates of Klebsiella pneumoniae (including about 67% of strains producing extended-spectrum, beta-lactamases and resistant to ciprofloxacin), Enterobacter cloacae, Pseudomonas aeruginosa with some activity against quinolone-resistant strains and Acinetobacter baumannii. The in vitro activity against anaerobes is comparable to imipenem or metronidazole. Sitafloxacin showed dual inhibitory activity against both enzymes: Streptococcus pneumoniae DNA gyrase and topoisomerase IV.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Topoisomerase IV 62 Target ID: CHEMBL2363033 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10588315	Inhibitor 8504
DNA gyrase 26 Target ID: CHEMBL2311225 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10588315	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Respiratory infections 12 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1597	Curative	Approved 8583	Gracevit(R) Approved Use It is usually used in the treatment of various infections such as respiratory infection, urologic infection, gynecologic infection, otorhinological infections, and dental infection. Launch Date 2008
Urologic infection 3 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1597	Curative	Approved 8583	Gracevit(R) Approved Use It is usually used in the treatment of various infections such as respiratory infection, urologic infection, gynecologic infection, otorhinological infections, and dental infection. Launch Date 2008
Gynecologic infections 19 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1597	Curative	Approved 8583	Gracevit(R) Approved Use It is usually used in the treatment of various infections such as respiratory infection, urologic infection, gynecologic infection, otorhinological infections, and dental infection. Launch Date 2008
Otorhinological infections 5 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1597	Curative	Approved 8583	Gracevit(R) Approved Use It is usually used in the treatment of various infections such as respiratory infection, urologic infection, gynecologic infection, otorhinological infections, and dental infection. Launch Date 2008
Dental infection 3 Sources: http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1597	Curative	Approved 8583	Gracevit(R) Approved Use It is usually used in the treatment of various infections such as respiratory infection, urologic infection, gynecologic infection, otorhinological infections, and dental infection. Launch Date 2008

C_max

Value	Dose	Analyte	Population
0.29 μg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_A100_2.pdf#page=35	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.51 μg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_A100_2.pdf#page=35	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1 μg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_A100_2.pdf#page=35 \| https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K101_2.pdf#page=6	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.86 μg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_A100_2.pdf#page=36	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.88 μg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K101_2.pdf#page=4	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
0.38 μg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K102_2.pdf#page=1	50 mg 2 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
0.5 μg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K102_2.pdf#page=1	50 mg 2 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
0.84 μg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K102_2.pdf#page=3	100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
1.09 μg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K102_2.pdf#page=3	100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
0.61 μg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K102_2.pdf#page=5	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.91 μg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K102_2.pdf#page=5	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.63 μg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K102_2.pdf#pag3=7	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.75 μg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K102_2.pdf#pag3=7	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.6 μg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K102_2.pdf#pag3=7	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3.44 μg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K128_2.pdf#page=10	400 mg 2 times / day multiple, intravenous dose: 400 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	SITAFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4.2 μg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K128_2.pdf#page=10	400 mg 2 times / day steady-state, intravenous dose: 400 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	SITAFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
5.08 μg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K128_2.pdf#page=10	600 mg 2 times / day multiple, intravenous dose: 600 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	SITAFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
6.44 μg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K128_2.pdf#page=10	600 mg 2 times / day steady-state, intravenous dose: 600 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	SITAFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7.18 μg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K128_2.pdf#page=10	800 mg 2 times / day multiple, intravenous dose: 800 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	SITAFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
9.07 μg/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K128_2.pdf#page=10	800 mg 2 times / day steady-state, intravenous dose: 800 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	SITAFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
1.52 μg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_A100_2.pdf#page=35	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.62 μg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_A100_2.pdf#page=35	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5.55 μg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_A100_2.pdf#page=35 \| https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K101_2.pdf#page=6	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
12.04 μg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_A100_2.pdf#page=36	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5.81 μg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K101_2.pdf#page=4	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
2.2 μg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K102_2.pdf#page=1	50 mg 2 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
2.71 μg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K102_2.pdf#page=1	50 mg 2 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
4.34 μg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K102_2.pdf#page=3	100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
5.9 μg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K102_2.pdf#page=3	100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
6.35 μg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K102_2.pdf#page=5	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.86 μg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K102_2.pdf#page=5	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.66 μg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K102_2.pdf#pag3=7	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
8.04 μg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K102_2.pdf#pag3=7	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
9.95 μg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K102_2.pdf#pag3=7	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
17.23 μg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K128_2.pdf#page=10	400 mg 2 times / day multiple, intravenous dose: 400 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	SITAFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
24.16 μg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K128_2.pdf#page=10	400 mg 2 times / day steady-state, intravenous dose: 400 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	SITAFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
27.32 μg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K128_2.pdf#page=10	600 mg 2 times / day multiple, intravenous dose: 600 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	SITAFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
39.12 μg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K128_2.pdf#page=10	600 mg 2 times / day steady-state, intravenous dose: 600 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	SITAFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
38.09 μg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K128_2.pdf#page=10	800 mg 2 times / day multiple, intravenous dose: 800 mg route of administration: Intravenous experiment type: MULTIPLE co-administered:	SITAFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
56.36 μg × h/mL OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K128_2.pdf#page=10	800 mg 2 times / day steady-state, intravenous dose: 800 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	SITAFLOXACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
5.2 h OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_A100_2.pdf#page=35	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
6.2 h OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_A100_2.pdf#page=35	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5.7 h OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_A100_2.pdf#page=35 \| https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K101_2.pdf#page=6	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5.3 h OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_A100_2.pdf#page=36	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5.5 h OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K101_2.pdf#page=4	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
5.1 h OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K102_2.pdf#page=1	50 mg 2 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
4.6 h OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K102_2.pdf#page=3	100 mg 2 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
6 h OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K102_2.pdf#page=5	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.3 h OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K102_2.pdf#page=5	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
7.5 h OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K102_2.pdf#pag3=7	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
11.5 h OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K102_2.pdf#pag3=7	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
16.3 h OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K102_2.pdf#pag3=7	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	SITAFLOXACIN serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
45% OTHER GOV'T https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_A100_2.pdf#page=35 \| https://www.pmda.go.jp/drugs/2008/P200800006/430574000_22000AMX00015_K101_2.pdf#page=6	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:		SITAFLOXACIN serum	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
100 mg 2 times / day multiple, oral Studied dose Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33534617/	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/33534617/	Other AEs: Diarrhea, Alanine aminotransferase increase... Other AEs: Diarrhea (3.3%) Alanine aminotransferase increase (7%) Fatigue (0.9%) Nausea (3.5%) Vomiting (0.9%) Dizziness (1.8%) Platelet count increased (0.9%) Aspartate aminotransferase increase (2.6%) Gamma-glutamyltransferase increased (2.6%) Sources: https://pubmed.ncbi.nlm.nih.gov/33534617/
400 mg 1 times / day multiple, intravenous Studied dose Dose: 400 mg, 1 times / day Route: intravenous Route: multiple Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/11020265/	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/11020265/	Other AEs: fever, Congestive cardiac failure... Other AEs: fever (6.33%) Congestive cardiac failure (7.39%) Diarrhea (9.5%) Skin rash (5.28%) Sources: https://pubmed.ncbi.nlm.nih.gov/11020265/

AEs

AE	Significance	Dose	Population
Fatigue	0.9%	100 mg 2 times / day multiple, oral Studied dose Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33534617/	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/33534617/
Platelet count increased	0.9%	100 mg 2 times / day multiple, oral Studied dose Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33534617/	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/33534617/
Vomiting	0.9%	100 mg 2 times / day multiple, oral Studied dose Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33534617/	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/33534617/
Dizziness	1.8%	100 mg 2 times / day multiple, oral Studied dose Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33534617/	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/33534617/
Aspartate aminotransferase increase	2.6%	100 mg 2 times / day multiple, oral Studied dose Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33534617/	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/33534617/
Gamma-glutamyltransferase increased	2.6%	100 mg 2 times / day multiple, oral Studied dose Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33534617/	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/33534617/
Diarrhea	3.3%	100 mg 2 times / day multiple, oral Studied dose Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33534617/	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/33534617/
Nausea	3.5%	100 mg 2 times / day multiple, oral Studied dose Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33534617/	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/33534617/
Alanine aminotransferase increase	7%	100 mg 2 times / day multiple, oral Studied dose Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/33534617/	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/33534617/
Skin rash	5.28%	400 mg 1 times / day multiple, intravenous Studied dose Dose: 400 mg, 1 times / day Route: intravenous Route: multiple Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/11020265/	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/11020265/
fever	6.33%	400 mg 1 times / day multiple, intravenous Studied dose Dose: 400 mg, 1 times / day Route: intravenous Route: multiple Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/11020265/	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/11020265/
Congestive cardiac failure	7.39%	400 mg 1 times / day multiple, intravenous Studied dose Dose: 400 mg, 1 times / day Route: intravenous Route: multiple Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/11020265/	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/11020265/
Diarrhea	9.5%	400 mg 1 times / day multiple, intravenous Studied dose Dose: 400 mg, 1 times / day Route: intravenous Route: multiple Dose: 400 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/11020265/	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/11020265/

PubMed

Title	Date	PubMed
[In vitro anti-MAC activities of new quinolones in focus (2)].	1996 Sep	8999137
In vitro activity of sitafloxacin against Clostridium difficile.	2001 May	11328798
A comparative study of the fluoroquinolone antibacterial agents on the action potential duration in guinea pig ventricular myocardia.	2001 Nov	11885973
Pharmacokinetics and absolute bioavailability of sitafloxacin, a new fluoroquinolone antibiotic, in healthy male and female Caucasian subjects.	2001 Nov	11765143
Phototoxic retinal degeneration and toxicokinetics of sitafloxacin, a quinolone antibacterial agent, in mice.	2001 Sep	11693179
Anti-Mycobacterium tuberculosis activities of new fluoroquinolones in combination with other antituberculous drugs.	2002 Apr	12099742
[Prospects for development of new antituberculous drugs].	2002 Aug	12235850
Antimicrobial activities of clarithromycin, gatifloxacin and sitafloxacin, in combination with various antimycobacterial drugs against extracellular and intramacrophage Mycobacterium avium complex.	2002 Feb	11850167
Photochemical behavior of sitafloxacin, fluoroquinolone antibiotic, in an aqueous solution.	2002 Feb	11848215
Trends in antimicrobial susceptibility of the Streptococcus milleri group.	2002 Jun	12111565
In vitro antibacterial activities of DQ-113, a potent quinolone, against clinical isolates.	2002 Mar	11850285
In vitro photochemical clastogenicity of quinolone antibacterial agents studied by a chromosomal aberration test with light irradiation.	2002 May 27	12034313
In vitro activity of sitafloxacin (DU-6859a) alone, or in combination with rifampicin, against Mycobacterium ulcerans.	2002 Nov	12407131
Sitafloxacin: DU 6859, DU 6859A, Gracevit, sitafloxacin hydrate.	2003	12568642
Comparative antimicrobial activities of gatifloxacin, sitafloxacin and levofloxacin against Mycobacterium tuberculosis replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines.	2003 Aug	12865388
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 2: achieving activity in vivo through the use of alternative scaffolds.	2003 Dec 1	14623002
Activities of sitafloxacin (DU-6859a), either singly or in combination with rifampin, against Mycobacterium ulcerans infection in mice.	2003 Feb	12678414
Detection of mutations in quinolone resistance-determining regions in levofloxacin- and methicillin-resistant Staphylococcus aureus: effects of the mutations on fluoroquinolone MICs.	2003 Jun	12812718
In vivo susceptibility of Mycobacterium leprae to sitafloxacin (DU-6859a), either singly or in combination with rifampicin analogues.	2003 Mar	12636987
Novel antibacterial agents for the treatment of serious Gram-positive infections.	2003 Mar	12605562
Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center.	2003 Nov	14563898
In vitro activities of 11 fluoroquinolones against 226 Campylobacter jejuni strains isolated from Finnish patients, with special reference to ciprofloxacin resistance.	2005 Dec	16223936
Quantitative assessment of the hepatic pharmacokinetics of the antimicrobial sitafloxacin in humans using in vivoF magnetic resonance spectroscopy.	2005 Feb	15676049
Acyl glucuronidation of fluoroquinolone antibiotics by the UDP-glucuronosyltransferase 1A subfamily in human liver microsomes.	2005 Jun	15769885
Reproducibility of gemifloxacin and comparison fluoroquinolone MIC results using Sensititre commercial dry-form panels.	2005 Mar	15766610
Characterization of fluoroquinolone and carbapenem susceptibilities in clinical isolates of levofloxacin-resistant Pseudomonas aeruginosa.	2005 May	15870499
Mutagenesis induced by 12 quinolone antibacterial agents in Escherichia coli WP2uvrA/pKM101.	2006 Apr	16171969
In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV.	2006 Dec	17056610
History and evolution of antibiotic resistance in coagulase-negative staphylococci: Susceptibility profiles of new anti-staphylococcal agents.	2007 Dec	18516271
Skin and skin structure infections: treatment with newer generation fluoroquinolones.	2007 Jun	18360639
Successful treatment of Mycobacterium ulcerans osteomyelitis with minor surgical debridement and prolonged rifampicin and ciprofloxacin therapy: a case report.	2008 Apr 27	18439310
Effects of treatment with antimicrobial agents on the human colonic microflora.	2008 Dec	19337440
Sitafloxacin hydrate for bacterial infections.	2008 Jul	18806900
Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae.	2008 Jul	18390884
Quinolones: action and resistance updated.	2009	19747119
Quinolones with enhanced bactericidal activity induce autolysis in Streptococcus pneumoniae.	2009	19468224
[In vitro susceptibilities to levofloxacin and various antibacterial agents of 12,919 clinical isolates obtained from 72 centers in 2007].	2009 Aug	19860322
Convulsant activity of sitafloxacin and its interactions with anti-inflammatory drugs in mice.	2009 Aug	19688249
[Present status and future prospect of 3rd rescue regimen for H. pylori infection].	2009 Dec	19999116
A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy.	2009 Dec 1	19935799
[Pharmacological profile and clinical efficacy of sitafloxacin, a novel quinolone antibacterial agent].	2009 Jan	19145050
[Clinical position of sitafloxacin in outpatient chemotherapy. (discussion)].	2009 Jun	19882979
Quinolone-Based Third-Line Therapy for Helicobacter pylori Eradication.	2009 Mar	19308265
Comparative mutant prevention concentration and mutant selection window of sitafloxacin versus other quinolones using strains of Haemophilus influenzae with decreasing susceptibility to levofloxacin.	2009 May	19150226
Susceptibility and bactericidal activity of 8 oral quinolones against conventional-fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates.	2009 Sep	19679241
In vivo efficacy of sitafloxacin in a new murine model of non-typeable Haemophilus influenzae pneumonia by sterile intratracheal tube.	2009 Sep	19394203
Characterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in Canada.	2010 Jan 18	20082699
Changes in 12-Year First-Line Eradication Rate of Helicobacter pylori Based on Triple Therapy with Proton Pump Inhibitor, Amoxicillin and Clarithromycin.	2010 Jul	20664731
In vitro susceptibility to antimicrobial agents and ultrastructural characteristics related to swimming motility and drug action in Campylobacter jejuni and C. coli.	2010 Jun	20225076
[Susceptibility test of the Mycobacterium avium complex to sixteen anti-infective agents].	2010 May	20646615

Patents

Sample Use Guides

In Vivo Use Guide

for adults: 1 tablet (50 mg of sitafloxacin) at a time, twice daily, or 2 tablets (100 mg) at a time, once daily. If the effect is insufficient, the dosage may be increased to 2 tablets (100 mg) at a time, twice daily.

Route of Administration: Oral

In Vitro Use Guide

The minimum inhibitory concentration of sitafloxacin (STFX) at which 90% of isolates (MIC90) was 0.5 microg/mL for methicillin-susceptible Staphylococcus aureus. STFX inhibited the growth of all the isolates of Streptococcus pneumoniae at 0.06 microg/mL or less. The MIC90 of STFX was 0.03 microg/mL. Against Streptococcus pyogenes, the MIC90 of STFX was 0.06 microg/mL. The MIC90 of STFX was 2 microg/mL for Enterococcus faecalis. The MIC90 of STFX for Escherichia coli was 2 microg/mL. The MIC90 of STFX for Pseudomonas aeruginosa isolates recovered from urinary infections was 4 microg/mL. The MIC90 of STFX for P. aeruginosa isolates recovered from respiratory infections was 4 microg/mL. STFX inhibited the growth of all the isolates of Haemophilus influenzae at 0.004 microg/mL or less. The MIC90 of STFX was 0.015 microg/mL for Moraxella catarrhalis. The MIC90(s) of STFX ranged from 0.03 to 0.25 microg/mL for all the species of anaerobic bacteria and were the lowest values of all the antimicrobial agents tested

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:57:21 GMT 2025` Edited by `admin` on `Mon Mar 31 17:57:21 GMT 2025`
Record UNII	45IP57B62B
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

3-QUINOLINECARBOXYLIC ACID, 7-((7S)-7-AMINO-5-AZASPIRO(2.4)HEPT-5-YL)-8-CHLORO-6-FLUORO-1-((1R,2S)-2-FLUOROCYCLOPROPYL)-1,4-DIHYDRO-4-OXO-, HYDRATE (1:1)

Preferred Name

English

SITAFLOXACIN MONOHYDRATE

Common Name

English

3-QUINOLINECARBOXYLIC ACID, 7-(7-AMINO-5-AZASPIRO(2.4)HEPT-5-YL)-8-CHLORO-6-FLUORO-1-(2-FLUOROCYCLOPROPYL)-1,4-DIHYDRO-4-OXO-, MONOHYDRATE, (1R-(1.ALPHA.(S*),2.ALPHA.))-

Common Name

English

Code System Code Type Description

FDA UNII

45IP57B62B

Created by admin on Mon Mar 31 17:57:21 GMT 2025 , Edited by admin on Mon Mar 31 17:57:21 GMT 2025

PRIMARY

CAS

163253-37-0

Created by admin on Mon Mar 31 17:57:21 GMT 2025 , Edited by admin on Mon Mar 31 17:57:21 GMT 2025

PRIMARY

PUBCHEM

6918203

Created by admin on Mon Mar 31 17:57:21 GMT 2025 , Edited by admin on Mon Mar 31 17:57:21 GMT 2025

PRIMARY

Related Record Type Details


					3GJC60U4Q8

SITAFLOXACIN ANHYDROUS

PARENT -> SALT/SOLVATE

Amount:


					3GJC60U4Q8

SITAFLOXACIN ANHYDROUS

ANHYDROUS->SOLVATE

Amount:

Related Record Type Details


					3GJC60U4Q8

SITAFLOXACIN ANHYDROUS

ACTIVE MOIETY

Amount:

Details

SMILES

InChI

DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/21504249Curator's Comment: description was created based on several sources, including http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1597 https://www.ncbi.nlm.nih.gov/pubmed/18806900 https://www.ncbi.nlm.nih.gov/pubmed/10588315

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Funbound

Doses

AEs

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21504249
Curator's Comment: description was created based on several sources, including http://www.rad-ar.or.jp/siori/english/kekka.cgi?n=1597 https://www.ncbi.nlm.nih.gov/pubmed/18806900 https://www.ncbi.nlm.nih.gov/pubmed/10588315

C_max

T_1/2

F_unbound